Targeting Nociceptors in Hidradenitis Suppurativa
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorUniversity of Massachusetts, Worcester
About this trial
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS)
HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas
Age < 18 years or > 75 years
pregnant or breastfeeding
Disqualifiers
None
Trial population
The study population will consist of men or women between the ages of 18-75 who have an established diagnosis of Hidradenitis Suppurativa who will undergo botulinum toxin treatment as part of routine care.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Botulinum toxin
DrugAdministration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: single group assignment1 intervention
Trial outcomes
Primary outcomes
1
Quantification and phenotyping of skin resident dendritic cell, macrophage, and T cell populations in patients before and after intralesional Botox treatment.
immune cell phenotyping
Time frame
1-2 months after first treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Massachusetts, Worcester
Lead sponsor
Hidradenitis Suppurativa Foundation
Collaborator
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator
AbbVie
Collaborator
Source ClinicalTrials.gov